Trial results suggested the antibody-drug conjugate may be a treatment option for patients with HER2 metastatic breast cancer ...

Jennifer McNeill claimed she visited her GP and A&E several times, but was told it was muscular. A mum who struggled to lift ...

Black women are more likely to be affected by breast cancer compared to their counterparts. A new FDA ruling can improve ...

October marks a critical month for women as it is designated Breast Cancer Awareness Month, a time to underscore the ...

PEOPLE and Verywell Health teamed up to bring you the latest insight into breast cancer treatments and outcomes, as well as ...

ORLANDO, Fla. — A new report shows breast cancer is claiming fewer lives in the U.S. The number of deaths is down 44% since ...

MU Health’s Ellis Fischel Cancer Center in Columbia is a cancer treatment and research hub. Dr. Nicole Nelson said innovative ...

Informing patients of their breast density results from a mammogram is now mandated by the Food and Drug Administration.

Michelle Danforth-Anderson is the Oneida Nation Marketing and Tourism Director, but she is also a two-time breast cancer ...

Trastuzumab deruxtecan is a HER2-directed antibody and topoisomerase inhibitor conjugate currently marketed under the brand name Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of breast ...

With this year's Breast Cancer Awareness Month now underway, we are sharing eight facts and updates about breast cancer that ...

The FDA expects to issue a decision in the first quarter of 2025, and if the agency grants approval, it will expand the biomarker-eligible population for the drug.